Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus;Efectividad y tolerabilidad a 6 meses de la pioglitazona en combinación con sulfonilureas o metformina en el tratamiento de la diabetes mellitus tipo 2

Medicina Clinica

Volumn 131, Issue 19, 2008, Pages 721-730

  Rodríguez, Ángel ^a   Reviriego, Jesús ^a   Polavieja, Pepa ^a   Mesa, Jordi ^b  

^a Lilly SA Alcobendas   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cohort studies; Diabetes mellitus type 2; Insulin resistance; Pioglitazone

Indexed keywords

CHOLESTEROL; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PHYSICIAN; PROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 63149110121     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/S0025-7753(08)75486-1     Document Type: Article

References (46)

1. Passa P. Diabetes trends in Europe. Diabetes Metab Res Rev 18 Suppl 3 (2002) 3-8
2. Rosenbloom A.L., Joe J.R., Young R.S., and Winter W.E. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22 (1999) 345-354
3. Goday A. Epidemiología de la diabetes y sus complicaciones no coronarias. Rev Esp Cardiol 55 (2002) 657-670
4. Valdés S., Rojo-Martínez G., and Soriguer F. Evolución de la prevalencia de la diabetes tipo 2 en población adulta española. Med Clin (Barc) 129 (2007) 352-355
5. Oliva J., Lobo F., Molina B., and Monereo S. Direct health care costs of diabetic patients in Spain. Diabetes Care 27 (2004) 2616-2621
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
8. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
9. Arroyo J., Badia X., De la Calle H., Díez J., Esmatjes E., Fernández I., et al. Tratamiento de los pacientes con diabetes mellitus tipo 2 en atención primaria en España. Med Clin (Barc) 125 (2005) 166-172
10. Álvarez-Sala L.A., Suárez C., Mantilla T., Franch J., Ruilope L.M., Banegas J.R., et al. Estudio PREVENCAT: control del riesgo cardiovascular en atención primaria. Med Clin (Barc) 124 (2005) 406-410
11. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 25 Suppl 1 (2002) 5-20
12. National Cholesterol Education Program Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (ATP III). National Cholesterol Education Program. Washington, DC: Department of Health and Human Services. National Heart, Lung and Blood Institute. National Institutes of Health; 2002.
13. Grundy S.M. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol 83 (1999) 25F-29F
14. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
15. Stumvoll M., Goldstein B.J., and Van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
16. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287 (2002) 360-372
17. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., and Schneider R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23 (2000) 1605-1611
18. Horton E.S., Whitehouse F., Ghazzi M.N., Venable T.C., and Whitcomb R.W. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care 21 (1998) 1462-1469
19. Einhorn D., Rendell M., Rosenzweig J., Egan J.W., Mathisen A.L., and Schneider R.L. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 22 (2000) 1395-1409
20. Hanefeld M., and Göke B. Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes. Exp Clin Endocrinol Diabetes 108 (2000) 256-266
21. Hanefeld M., Pfutzner A., Forst T., and Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin 22 (2006) 1211-1215
22. Schöfl C., and Lübben G. Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice. Clin Drug Investig 23 (2003) 725-734
23. Sociedad Española para el Estudio de la Obesidad. Consenso SEEDO'2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin (Barc) 115 (2000) 587-597
24. Expert Panel on the Identification Evaluation and Treatment of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. Washington, DC: Department of Health and Human Services. National Heart, Lung and Blood Institute. National Institutes of Health; 1998.
25. Wilson S., Johnston A., Robson J., Poulter N., Collier D., Feder G., et al. Comparison of methods to identify individuals at increased risk of coronary disease from the general population. BMJ 326 (2003) 1436
26. Dobiasova M., and Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 34 (2001) 583-588
27. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 16 (1999) 716-730
28. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management - 2000 update. Endocr Pract. 2000;6:43-84.
29. Kipnes M.S., Krosnick A., Rendell M.S., Egan J.W., Mathisen A.L., and Schneider R.L. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 111 (2001) 10-17
30. Hsueh W.A., Jackson S., and Law R.E. Control of vascular cell proliferation and migration by PPARgamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 24 (2001) 392-397
31. Kotchen T.A., Zhang H.Y., Reddy S., and Hoffmann R.G. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol 270 (1996) R660-R666
32. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., and Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007) 459-467
33. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino R.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
34. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
35. Assmann G., and Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 70 (1992) 733-737
36. Gordon D.J., Probstfield J.L., Garrison R.J., Neaton J.D., Castelli W.P., Knoke J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
37. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Manttari M., Heinonen O.P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85 (1992) 37-45
38. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
39. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (1999) 410-418
40. Schaefer E.J., Lamon-Fava S., Ordovas J.M., Cohn S.D., Schaefer M.M., Castelli W.P., et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 35 (1994) 871-882
41. Tack C.J., Smits P., Demacker P.N., and Stalenhoef A.F. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 21 (1998) 796-799
42. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
43. Steiner G. Risk factors for macrovascular disease in type 2 diabetes. Classic lipid abnormalities. Diabetes Care 22 Suppl 3 (1999) 6-9
44. Relimpio F., Martínez-Brocca M.A., Leal-Cerro A., Losada F., Mangas M.A., Pumar A., et al. Variability in the presence of the metabolic syndrome in type 2 diabetic patients attending a diabetes clinic. Influences of age and gender. Diabetes Res Clin Pract 65 (2004) 135-142
45. Bailey C.J. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 7 (2005) 675-691
46. Kunz R., and Oxman A.D. The unpredictability paradox: review of empirical comparisons of randomized and non-randomised clinical trials. BMJ 317 (1998) 1185-1190